Clinical severity classes in COVID-19 pneumonia have distinct immunological profiles, facilitating risk stratification by machine learning.
COVID-19
biomarker
complement
cytokine
machine learning
nomacopan
risk stratification
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
03
2023
accepted:
25
07
2023
medline:
22
9
2023
pubmed:
21
9
2023
entrez:
21
9
2023
Statut:
epublish
Résumé
Clinical triage in coronavirus disease 2019 (COVID-19) places a heavy burden on senior clinicians during a pandemic situation. However, risk stratification based on serum biomarker bioprofiling could be implemented by a larger, nonspecialist workforce. Measures of Complement Activation and inflammation in patientS with CoronAvirus DisEase 2019 (CASCADE) patients ( The LDA models distinctly discriminated between deteriorators, nondeteriorators, and HC, with IL-27, IP-10, MDC, ferritin, C5, and sC5b-9 among the key predictor variables during deterioration. C3a and C5 were elevated in all severity classes vs. HC ( Distinct immunological fingerprints from serum biomarkers exist within different severity classes of COVID-19, and harnessing them using machine learning enabled the development of clinically useful triage and prognostic tools. Complement-mediated lung injury plays a key role in COVID-19 pneumonia, and preliminary results hint at the usefulness of a C5 inhibitor in COVID-19 recovery.
Identifiants
pubmed: 37731491
doi: 10.3389/fimmu.2023.1192765
pmc: PMC10508987
doi:
Substances chimiques
Interleukin-27
0
Immunosuppressive Agents
0
Banques de données
ClinicalTrials.gov
['NCT04453527']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1192765Informations de copyright
Copyright © 2023 Wiffen, D’Cruz, Brown, Higenbottam, Bernstein, Campbell, Moellman, Ghosh, Richardson, Weston-Davies and Chauhan.
Déclaration de conflit d'intérêts
Authors TH, CR, and WW-D are employed by AKARI Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Immun Inflamm Dis. 2021 Dec;9(4):1186-1196
pubmed: 34472718
J Vis Exp. 2010 Mar 29;(37):
pubmed: 20351687
Transl Res. 2021 May;231:55-63
pubmed: 33221483
J Allergy Clin Immunol. 2020 Jul;146(1):119-127.e4
pubmed: 32360286
Biom J. 2008 Jun;50(3):419-30
pubmed: 18435502
J Allergy Clin Immunol. 2021 Jan;147(1):81-91
pubmed: 32979342
Scand J Clin Lab Invest. 2020 Nov;80(7):536-540
pubmed: 32804580
J Clin Pharm Ther. 2020 Dec;45(6):1515-1519
pubmed: 32860252
Am J Pathol. 2020 Jun;190(6):1138-1150
pubmed: 32194049
Cytokine. 2021 Feb;138:155389
pubmed: 33348065
Int Immunol. 2017 Nov 1;29(9):401-409
pubmed: 28541437
Lancet. 2021 Aug 14;398(10300):599-607
pubmed: 34332652
Front Immunol. 2020 Nov 10;11:585108
pubmed: 33240274
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Thromb Haemost. 2020 Sep;18(9):2110-2117
pubmed: 32608159
JCI Insight. 2020 Aug 6;5(15):
pubmed: 32554923
NPJ Digit Med. 2021 Feb 26;4(1):40
pubmed: 33637833
J Crit Care. 2022 Feb;67:172-181
pubmed: 34808527
Biol Blood Marrow Transplant. 2016 Jul;22(7):1337-1340
pubmed: 27060440
Int J Gen Med. 2020 Dec 31;13:1705-1711
pubmed: 33408508
Int J Infect Dis. 2020 Aug;97:303-305
pubmed: 32497811
Nat Rev Immunol. 2022 Oct;22(10):639-649
pubmed: 35931818
Nat Rev Immunol. 2020 Jun;20(6):343-344
pubmed: 32327719
Int J Mol Sci. 2022 Nov 22;23(23):
pubmed: 36498859
Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5411-6
pubmed: 22431590
Blood. 2020 Oct 29;136(18):2080-2089
pubmed: 32877502
Eur Respir Rev. 2021 Oct 20;30(162):
pubmed: 34670808
Clin Exp Allergy. 2010 Feb;40(2):200-8
pubmed: 19906013
Br J Haematol. 2020 Jan;188(2):334-337
pubmed: 31840801
Heart. 2020 Aug;106(15):1154-1159
pubmed: 32354798
Front Immunol. 2023 Jan 24;14:1082830
pubmed: 36761773
Acta Biomed. 2020 Nov 10;91(4):e2020162
pubmed: 33525236
Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9162-7
pubmed: 10908681
J Pathol. 2022 Jul;257(4):413-429
pubmed: 35579955
Nat Rev Microbiol. 2008 Jul;6(7):541-52
pubmed: 18552864
Eur Respir J. 2002 Oct;20(4):990-5
pubmed: 12412694
Ger Med Sci. 2010 Sep 08;8:
pubmed: 20930931
Am J Emerg Med. 2020 Mar;38(3):641-647
pubmed: 31785981
Front Immunol. 2022 Jul 25;13:964179
pubmed: 35958594
JAMA Dermatol. 2022 Jun 1;158(6):641-649
pubmed: 35507334
Nurs Outlook. 2016 Jul-Aug;64(4):292-298
pubmed: 27298194
Front Immunol. 2021 Aug 20;12:681516
pubmed: 34489933
J Clin Invest. 2019 Mar 18;129(4):1452-1462
pubmed: 30882368
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Front Pharmacol. 2022 Jan 12;12:808797
pubmed: 35095519
Virol J. 2021 Jan 7;18(1):12
pubmed: 33413449
Front Immunol. 2021 Jul 05;12:714511
pubmed: 34290717
Shock. 2005 Jan;23(1):39-44
pubmed: 15614130
Am J Med Sci. 2021 Jan;361(1):14-22
pubmed: 33187633
J Clin Invest. 2013 Sep;123(9):3967-82
pubmed: 23945235
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409
pubmed: 32270184
Immunology. 2023 Mar;168(3):473-492
pubmed: 36175370
J Clin Med. 2021 May 08;10(9):
pubmed: 34066892
Nat Commun. 2021 Oct 19;12(1):6086
pubmed: 34667172
Arch Surg. 1992 Oct;127(10):1219-24
pubmed: 1417490
Int J Inflam. 2011;2011:908468
pubmed: 22235381
Rev Med Virol. 2021 Nov;31(6):e2221
pubmed: 34773448